Literature DB >> 7944343

Aspects of antibody-catalyzed primary amide hydrolysis.

R C Titmas1, T S Angeles, R Sugasawara, N Aman, M J Darsley, G Blackburn, M T Martin.   

Abstract

Because there are many known C-terminally amidated peptides of biological importance, there is great potential in medicine and organic synthesis for antibodies that catalyze primary amide bond hydrolysis or formation. We characterized a catalytic antibody, 13D11, raised to a phosphinate hapten, that hydrolyzed the primary amide of a dansyl-alkylated derivative of (R)-phenylalaninamide (DNS-(R)F-NH2). At pH 9.0, 13D11 hydrolyzed DNS-(R)F-NH2 with a kcat of 1.65 x 10(-7) s-1 (kcat/kuncat = 132) and a Km of 432 microM, and was stereospecifically hapten-inhibited (Ki = 14.0 microM). Control experiments indicated that the catalytic activity was not the result of a contaminating protease. In accordance with the hapten being a transition-state analog of base hydrolysis, the rate of DNS-(R)F-NH2 hydrolysis increased with hydroxide concentration to an optimum pH of 9.5. Above pH 9.5, activity declined rapidly suggesting the antibody was inactivated during the long incubation period. This work demonstrates the feasibility of generating catalytic antibodies to hydrolyze unactivated amide bonds without cofactor assistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944343     DOI: 10.1007/bf02787940

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  34 in total

Review 1.  Designer and catalytic antibodies.

Authors:  R D Mayforth; J Quintáns
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

2.  Catalytic antibodies.

Authors:  A Tramontano; K D Janda; R A Lerner
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

Review 3.  Generation of cytotoxic agents by targeted enzymes.

Authors:  P D Senter; P M Wallace; H P Svensson; V M Vrudhula; D E Kerr; I Hellström; K E Hellström
Journal:  Bioconjug Chem       Date:  1993 Jan-Feb       Impact factor: 4.774

4.  CGRP antagonist activity of short C-terminal fragments of human alpha CGRP, CGRP(23-37) and CGRP(19-37).

Authors:  P Rovero; S Giuliani; C A Maggi
Journal:  Peptides       Date:  1992 Sep-Oct       Impact factor: 3.750

5.  Conformation-activity relationship of tachykinin neurokinin A (4-10) and of some [Xaa8] analogues.

Authors:  G Saviano; P A Temussi; A Motta; C A Maggi; P Rovero
Journal:  Biochemistry       Date:  1991-10-22       Impact factor: 3.162

6.  Micelle-bound conformations of a bombesin/gastrin releasing peptide receptor agonist and an antagonist by two-dimensional NMR and restrained molecular dynamics.

Authors:  J A Malikayil; J V Edwards; L R McLean
Journal:  Biochemistry       Date:  1992-08-11       Impact factor: 3.162

7.  Semisynthesis of human growth hormone-releasing factors by alpha-amidating enzyme catalyzed oxidation of glycine-extended precursors.

Authors:  J Bongers; A M Felix; R M Campbell; Y Lee; D J Merkler; E P Heimer
Journal:  Pept Res       Date:  1992 Jul-Aug

8.  Substance K: a novel mammalian tachykinin that differs from substance P in its pharmacological profile.

Authors:  H Nawa; M Doteuchi; K Igano; K Inouye; S Nakanishi
Journal:  Life Sci       Date:  1984-03-19       Impact factor: 5.037

Review 9.  The calcitonin gene peptides: biology and clinical relevance.

Authors:  M Zaidi; B S Moonga; P J Bevis; Z A Bascal; L H Breimer
Journal:  Crit Rev Clin Lab Sci       Date:  1990       Impact factor: 6.250

10.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

Authors:  L A Clavell; R D Gelber; H J Cohen; S Hitchcock-Bryan; J R Cassady; N J Tarbell; S R Blattner; R Tantravahi; P Leavitt; S E Sallan
Journal:  N Engl J Med       Date:  1986-09-11       Impact factor: 91.245

View more
  1 in total

Review 1.  On the failure of de novo-designed peptides as biocatalysts.

Authors:  M J Corey; E Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.